biote Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTMD research report →
Range $2.5 – $4
Price Chart
About the company
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels.
- CEO
- Robert C. Peterson
- IPO
- 2021
- Employees
- 223
- HQ
- Irving, TX, US
Get TickerSpark's AI analysis on BTMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $35.93M
- P/E
- -10.57
- Fwd P/E
- 5.16
- PEG
- 0.10
- P/S
- 0.20
- P/B
- -0.34
- EV/EBITDA
- 9.78
- Div Yield
- 0.00%
- Gross Margin
- 58.95%
- Op Margin
- 5.02%
- Net Margin
- -1.08%
- ROE
- 3.13%
- ROIC
- -5.90%
Latest fiscal year · YoY change
- Revenue
- $192.22M-2.5%
- Gross Profit
- $137.36M-1.2%
- Op Income
- $35.55M
- Net Income
- $27.05M+756.7%
- EPS
- $0.86+833.8%
- OCF Growth
- -22.2%
- FCF Growth
- -22.2%
- 52W High
- $2.90
- 52W Low
- $0.81
- 50D MA
- $1.14
- 200D MA
- $1.74
- Beta
- 1.74
- RSI (14)
- 32
- Avg Volume
- 146.21K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Biote reported a softer third quarter with revenue and procedure volume down year over year, but management said procedure trends are stabilizing and kept full-year guidance unchanged.· November 4, 2026
- Revenue fell 9.6% year over year to $43.3 million, with procedure revenue down 15.1% to $28.9 million.
- Gross margin was 67.7%, down from 71.8%, though it improved 31 basis points sequentially as more pellets shifted back to internal manufacturing.
- Adjusted EBITDA was $5.1 million, or 11.7% margin; net income was $600 thousand and EPS was $0.01.
- Management said recent procedure volume trends are encouraging, but growth is progressing more slowly than expected because of the January 2026 recall and a sales-force reset.
- Full-year 2026 guidance was maintained at revenue above $175 million and adjusted EBITDA above $25 million.
Third-quarter revenue decreased 9.6% year over year to $43.3 million. Procedure revenue declined 15.1% to $28.9 million, while dietary supplements revenue grew 7.3% to $12 million. Gross margin was 67.7% versus 71.8% a year ago; on a sequential basis, gross margin improved 31 basis points from Q2 as the mix shifted back toward internally manufactured pellets. SG&A increased 2.6% to $26.8 million. Net income was $600 thousand and diluted EPS was $0.01, versus net income of $9.2 million and EPS of $0.22 last year. Adjusted EBITDA fell to $5.1 million with a margin of 11.7%, and operating cash flow was $3.7 million. Cash and cash equivalents were $8.9 million at 9/30/2026, down from $11.2 million at 6/30/2026. Management reiterated full-year 2026 guidance of revenue above $175 million and adjusted EBITDA above $25 million.
Bob Peterson’s message was that the business is in a turnaround phase centered on two priorities: increasing sales productivity and strengthening practitioner engagement. He said procedure volume showed early signs of stabilization, but the return to growth is taking longer than hoped because of the recall impact, a large sales-team upgrade, and the time needed to rebuild clinic pipelines. His tone was constructive but candid, emphasizing data-driven accountability, more face-to-face rep activity, and better clinic support as the path to improved growth.
Peterson, acting as CFO on the call, gave a detailed financial readout: revenue was $43.3 million, gross margin 67.7%, SG&A $26.8 million, adjusted EBITDA $5.1 million, and cash $8.9 million. He attributed the gross-margin decline mainly to residual recall effects and higher use of lower-margin third-party pellets, but noted sequential improvement and said further margin gains should come as Asteria returns to higher shipment levels; he said Asteria will supply over 50% of shipped pellets, versus 30% in Q2. He also said SG&A fell 20.8% sequentially due mostly to lower legal settlements, and that the company continues to invest in product and technology while managing capital efficiency. Full-year guidance remained revenue above $175 million and adjusted EBITDA above $25 million.
Analysts pressed for clarity on whether procedure declines were stabilizing or improving, what internal metrics show the sales and engagement initiatives are working, and how management thinks about new customer growth versus retention. Peterson said the quarter showed modest average daily procedure volume increases, but the key remains more face-to-face rep activity, better clinic onboarding, and stronger same-store sales. On why growth has been slower than hoped, he pointed to the recall-related disruption, the addition of roughly 50 new sales reps, and the time required to rebuild pipelines and culture. He also said he has not seen a major shift in practitioner economics or consumer behavior, and that consumers remain fairly strong.
The constructive case is that management believes procedure trends are starting to stabilize and that the recall-related disruption is fading. Gross margin already improved sequentially, and management expects more improvement as internally manufactured pellets regain mix and Asteria returns to pre-recall levels. The new data-driven sales approach, plus a more active field force and stronger clinical education, could help restore productivity and clinic retention.
The main risk is that the recovery is slower than management had hoped, with procedure revenue still down sharply and profitability well below last year. The recall caused meaningful disruption, and management acknowledged that rebuilding sales pipelines and changing the sales culture will take time. Cash also declined to $8.9 million, and the company said it is still working through a period of organizational change and uneven clinic performance.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.0%
- Shares Outstanding
- 44.11M
- Float Shares
- 40.14M
of shares held by institutions
73 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| 325 Capital LLC | 4.55M | 0 |
| Vanguard Group Inc | 1.44M | ▲ 17.78K |
| Vanguard Capital Management LLC | 1.09M | ▼ 11.44K |
| Bandera Partners LLC | 707.07K | ▼ 1.36M |
| Acadian Asset Management LLC | 586.74K | ▼ 38.65K |
| Dimensional Fund Advisors LP | 423.96K | ▼ 8.00K |
| Millennium Management LLC | 371.21K | ▼ 64.88K |
| Blackrock, Inc. | 348.67K | ▼ 17.27K |
| Geode Capital Management, LLC | 242.08K | ▼ 18.41K |
| Renaissance Technologies LLC | 235.39K | ▲ 5.40K |
| Rice Hall James & Associates, LLC | 207.85K | ▼ 54.99K |
| Perritt Capital Management Inc | 146.25K | ▲ 6.00K |
Held by 29 ETFs
Biggest fund positions in BTMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 26 | Beer Marc D | buy | 16,000 |
| Aug 10, 26 | Beer Marc D | buy | 115,950 |
| Jun 12, 26 | Peterson Robert Charles | other | 206,746 |
| Jun 8, 26 | Christensen Bret | other | 130,000 |
| Jun 8, 26 | Beer Marc D | other | 114,157 |
| May 12, 26 | HEYER ANDREW R | other | 130,000 |
| May 12, 26 | HEYER ANDREW R | other | 35,259 |
| May 12, 26 | MORRIS DEBRA L | other | 130,000 |
| May 12, 26 | MORRIS DEBRA L | other | 21,407 |
| May 12, 26 | MORRIS DEBRA L | other | 39,036 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BTMD coverage
Recent articles, reports, and earnings notes.
No research on BTMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BTMD report →biote: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 16
biote Corp. (BTMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
biote Corp. (BTMD) Tops Q3 Earnings Estimates
zacks.com · Nov 4
Biote Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 4
Head-To-Head Survey: The Pennant Group (NASDAQ:PNTG) vs. biote (NASDAQ:BTMD)
defenseworld.net · Oct 22
Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call
businesswire.com · Oct 21
biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) Head to Head Review
defenseworld.net · Oct 10
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.